Fresenius Medical Care AG & Co KGaA
NYSE:FMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (4.9), the stock would be worth $27.83 (22% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4 | $22.77 |
0%
|
| 3-Year Average | 4.9 | $27.83 |
+22%
|
| 5-Year Average | 5 | $27.9 |
+23%
|
| Industry Average | 12.9 | $72.63 |
+219%
|
| Country Average | 8.7 | $48.96 |
+115%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
NYSE:FMS
|
10.8B USD | 4 | 11.1 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 9.3 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 8.3 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 0 | 12.5 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 8.5 | 23.3 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 8.8 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 11.8 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 13.2 | 24.8 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | -62.9 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 5.6 | 14.1 | |
| US |
|
Brightspring Health Services Inc
NASDAQ:BTSG
|
9.3B USD | 0 | 0 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 5.5 |
| Median | 8.7 |
| 70th Percentile | 14 |
| Max | 2 516.3 |
Other Multiples
Fresenius Medical Care AG & Co KGaA
Glance View
Fresenius Medical Care AG & Co KGaA, articulating a saga of innovation and resilience, stands at the global forefront of dialysis care. Born out of a convergence of medical expertise and humanitarian ambition, the company caters to individuals battling chronic kidney disease. It operates through an intricate network of dialysis clinics and manufacturing facilities spread across continents. These clinics are the lifeline for many, transforming what is essentially a life-threatening condition into a manageable routine. The process is remarkable: patients are connected to dialysis machines, many of which are crafted by Fresenius itself. These machines emulate the essential functions of kidneys by filtering and purifying blood, a process pivotal for sustaining life in those with kidney failure. The dual avenues of Fresenius Medical Care's revenue generation create a unique synergy driving the company's success. One arm of its business involves providing essential dialysis treatments through its expansive clinic network, offering healthcare services directly to patients worldwide. The other arm engages in the production and sale of dialysis products, encompassing everything from dialysis machines to a wide range of associated medical supplies. Hospitals and other healthcare providers across the globe depend on these products, further broadening Fresenius's impact and revenue streams. This symbiotic integration of services and products not only reinforces its market leadership but also aligns the company's growth with advancements in patient outcomes and healthcare technology.